Sales launch of Intervacc vaccine against equine Strangles during Q1 2022
Stockholm, December 14, 2021 - Intervacc AB (“Intervacc”) announces today that sales of the company’s Strangles vaccine Strangvac are planned to begin in the first quarter of 2022. Intervacc's vaccine against equine Strangles, a widespread and common infectious disease that affects horses globally, was granted marketing authorization for the European Union in the autumn, followed by approvals for the United Kingdom, Norway and Iceland. “We have produced vaccine for launch in Sweden and European markets. Production has gone well and we expect the vaccine doses to be released in January